The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

Panelist discusses how HS Centers of Excellence demonstrate potential for enhanced health care delivery through coordinated, specialized care approaches, with managed care organizations driving adoption through strategic incentives and collaborative frameworks.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

Now Viewing

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

Video content above is prompted by the following:

• What evidence supports the potential for improved outcomes through HS Centers of Excellence?
• How can managed care organizations encourage the adoption of coordinated care practices within these centers?

Related Videos

Related Content

Advertisement

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 13th 2025

Cuts to PEPFAR Spell Detrimental HIV Outcomes in South Africa

Julia Bonavitacola

HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 12th 2025

Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval

Giuliana Grossi

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral solution.

February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.

Related Content

Advertisement

February 14th 2025

Adults With DMD More Than Twice as Likely to Experience Fractures

Rose McNulty

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of osteoporosis in adult men with Duchenne muscular dystrophy (DMD).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 13th 2025

Cuts to PEPFAR Spell Detrimental HIV Outcomes in South Africa

Julia Bonavitacola

HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 12th 2025

Risdiplam Tablet for Spinal Muscular Atrophy Receives FDA Approval

Giuliana Grossi

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral solution.

February 12th 2025

High Prevalence of Sarcopenia Identified in Patients With Ovarian, Endometrial Cancer

Brooke McCormick

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early screening and preventive measures for these populations.